REGN Regeneron Pharmaceuticals Inc.

+7.38  (+2%)
Previous Close 302.57
Open 304.88
Price To Book 3.6
Market Cap 33982537381
Shares 109,638,772
Volume 999,925
Short Ratio
Av. Daily Volume 852,307

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA Approval announced September 28, 2018.
Cutaneous squamous cell carcinoma
FDA Approval announced August 17, 2018.
sBLA Approval announced April 25, 2017.
Praluent (alirocumab)
High low-density lipoprotein (LDL) cholesterol
Phase 3 data due 4Q 2019.
Dupixent (dupilumab)
Atopic dermatitis 6-11 year-olds
FDA approval announced March 11, 2019.
Dupixent (dupilumab)
Atopic dermatitis 12-17 year-olds
FDA approval announced April 26, 2019.
Praluent (alirocumab) ODYSSEY OUTCOMES
Cardiovascular events
FDA approval announced October 19, 2018.
Dupixent (dupilumab)
Pivotal Phase 2/3 trial ongoing.
Cutaneous squamous cell carcinoma
Phase 3 enrolling. Data due 2021.
Non-small cell lung cancer (NSCLC)
Phase 3 enrolling.
Non-small cell lung cancer (NSCLC)
Data due 2020.
Basal cell carcinoma
Phase 2 enrolling as of September 2017. BLA filing due 1Q 2018 pending data.
Basal cell carcinoma
Phase 3 trial met co-primary endpoints - August 16, 2018. Low dose arms only.
Moderate-to-severe osteoarthritis pain of the hip or knee
Phase 3 data released August 14, 2017 - primary endpoint not met.
Respiratory syncytial virus (RSV)
FDA Approval announced May 13, 2019.
Nonproliferative Diabetic Retinopathy
Phase 3 ongoing.
Diabetic Retinopathy
Phase 3 enrollment commenced 2Q 2017. Data due 2021.
Dupixent (dupilumab)
Asthma - 6-11 year-olds
PDUFA date under priority review June 26, 2019.
Dupixent (dupilumab)
Nasal polyps
Phase 2b placed on clinical hold. Phase 3 trial to be initiated that excludes patients with advanced osteoarthritis 2H 2017.
Osteoarthritis and chronic low back pain
Phase 2 data released November 27, 2017 - insufficient efficacy shown to warrant further development.
EYLEA + nesvacumab
Diabetic macular edema (DME)
Phase 2 data released November 27, 2017 - insufficient efficacy shown to warrant further development.
EYLEA + nesvacumab
AMD - age-related macular degeneration
Phase 2 trial to commence 2018.
Dupixent (dupilumab)
Peanut Allergy
Phase 3 trial commenced September 2018.
Dupixent (dupilumab)
Eosinophilic esophagitis
Approved under priority review - March 28, 2017.
Dupixent (dupilumab)
Atopic dermatitis
CRL October 28, 2016. Resubmitted with FDA Approval announced May 22, 2017.
Rheumatoid arthritis
Phase 2 trial to commence 1H 2019. Updated Phase 1 data due at EHA June 13-16, 2019.
Non-Hodgkin Lymphoma (NHL)
Phase 3 data due 2019.
Evinacumab (ANGPTL3 Antibody)
Homozygous familial hypercholesterolemia (HoFH)
Phase 2 data due 1Q 2020.
Chronic Obstructive Pulmonary Disease (COPD)
Phase 2 data due 2Q 2019.

Latest News

  1. 5 Oversold Stocks That Can Rebound Amid the Trade War
  2. Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study
  3. 5 Cheap Stocks to Ride Out the Trade War
  4. Edited Transcript of REGN earnings conference call or presentation 7-May-19 12:30pm GMT
  5. Moving Average Crossover Alert: Regeneron Pharmaceuticals
  6. Regeneron Cancer Drug Gives Anxious Investors Hope
  7. Outlook Therapeutics started at outperform with $12 stock price target at Oppenheimer
  8. Pfizer's Eczema Candidate Meets All Goals in Phase III Study
  9. Updated Libtayo® (cemiplimab-rwlc) Results Reinforce Durable and Substantial Response Rates in Advanced Cutaneous Squamous Cell Carcinoma
  10. Biotech Stock Roundup: FDA Nod for REGN's Eylea in DR, Tie-Ups & Other Updates
  11. Regeneron (REGN) Gets FDA Nod for Eylea Label Expansion
  12. The Daily Biotech Pulse: Further Delay in Roche's Spark Acquisition, FDA Nod For Regeneron, Solid Biosciences Sinks On Earnings
  13. FDA Approves EYLEA® (aflibercept) Injection for Diabetic Retinopathy
  14. 5 Growthy Biotech Stocks to Buy Despite the Scrutiny
  15. Inovio (INO) Q1 Earnings & Revenues Fall Short of Estimates
  16. Parnassus Endeavor Fund Buys 2 Pharmaceutical Stocks in 1st Quarter
  17. Here's the Bad News That Derailed Regeneron's Stock
  18. Regeneron Pharmaceuticals (REGN) Q1 2019 Earnings Call Transcript
  19. Regeneron Earnings: Slammed On Costs, Cancer Setback — Shares Dive